A proteomics based approach for the identification of gastric cancer related markers

Current Pharmaceutical Design

Volumn 22, Issue 7, 2016, Pages 804-811

  Sheikh, Ishfaq A ^a   Mirza, Zeenat ^a   Ali, Ashraf ^a   Aliev, Gjumrakch ^b,c,d   Ashraf, Ghulam Md ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b GALLY International Biomedical Research Consulting LLC   (United States)

^c University of Atlanta   (United States)

^d INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

Author keywords

Blood; Diagnosis; Gastric cancer; H. Pylori; Proteomics

Indexed keywords

CA 19-9 ANTIGEN; CA 50 ANTIGEN; CA 72-4 ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; PROTEOMICS; STOMACH CANCER; STOMACH JUICE; WORLD HEALTH ORGANIZATION; EARLY CANCER DIAGNOSIS; METABOLISM; METASTASIS; PATHOLOGY; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STOMACH MUCOSA; STOMACH NEOPLASMS; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; GASTRIC MUCOSA; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

EID: 84958582193     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151209151848     Document Type: Article

References (122)

1. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenter Hepatol Bed Bench 2015; 8(1): 19-27.
2. Jing J-J, Liu H-Y, Hao J-K, et al. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol 2012; 18(11): 1262-69.
3. Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol 2014; 20(16): 4483-90.
4. Qiu F-M, Yu J-K, Chen Y-D, Jin Q-F, Sui M-H, Huang J. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Cli Cancer Res 2009; 28(126): 7.
5. Dikshit RP, Mathur G, Mhatre S, Yeole BB. Epidemiological review of gastric cancer in India. Ind J Med Paed Oncol 2011; 32(1): 3-11.
6. Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastroenterol 2012; 4(7): 156-69.
7. Sharma A, Radhakrishnan V. Gastric cancer in India. Ind J Med Paed Oncol 2011; 32(1): 12-6.
8. Hussein NR. Helicobacter pylori and gastric cancer in the Middle East: A new enigma? World J Gastroenterol 2010; 16(26): 3226-34.
9. Al-Mahrouqi H, Parkin L, Sharples K. Incidence of stomach cancer in oman and the other gulf cooperation council countries. Oman Med J 2011; 26(4): 258-62.
10. Al-Radi AO, Ayyub M, Al-Mashat FM, et al. Primary gastrointestinal cancers in the Western Region of Saudi Arabia. Is the pattern changing? Saudi Med J 2000; 21(8): 730-4.
11. Hamdi J, Morad NA. Gastric cancer in southern Saudi Arabia. Ann Saudi Med 1994; 14(3) 195-7.
12. Bai Y, Fang N, Gu T, Kang Y, Wu J, Yang D, et al. HOXA11 gene is hypermethylation and aberrant expression in gastric cancer. Cancer Cell Int 2014; 14(79): 8.
13. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma. Ann Surg 2005; 241(1): 27-39.
14. Gastric Cancer: The Basics | Oncolink - Cancer Resources http://www.oncolink.org/types/article.cfm?c=152& id=9463.
15. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guide- line from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa De En-doscopia Digestiva (SPED). Endoscopy 2012; 44(1): 74-94.
16. Shi J, Qu Y-P, Hou P. Pathogenetic mechanisms in gastric cancer. World J Gastroenterol 2014; 20(38): 13804-19.
17. Watari J, Chen N, Amenta PS, et al. Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 2014; 20(18): 5461-73.
18. Tabrez S, Priyadarshini M, Urooj M, et al. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. J Environ Sci Health Part C Environ Carc Ecotox Rev 2013 31(1): 67-98.
19. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. Nanotechnology-based approaches in anticancer research. Int J Nanomed 2012; 7: 4391-408.
20. Ali R, Mirza Z, Ashraf GM, et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res 2012; 32(7):2999-3005.
21. Alexiou A, Vairaktarakis C, Tsiamis V, Ashraf GM. Application of efficient nanoparticles for early diagnosis and treatment of cancer. Curr Drug Metabol 2015; 16(8): 662-75.
22. Saka M, Morita S, Fukagawa T, Katai H. Present and future status of gastric cancer surgery. Jpn J Clin Oncol 2011; 41(3): 307-13.
23. Wang Z, Yang C, Yang Y, Shen Z, Zhao H, Yao Y. Clinical application value of bone turnover markers in non-small-cell lung cancer patients with bone metastases. Chin-Ger J Clin Onc 2011; 10(2): 81-4.
24. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
25. Hwang JJ, Lee DH, Lee A-R, et al. Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection. World J Gastroenterol 2015; 21(16): 4954-60.
26. Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol 2005; 90(3): 114-33.
27. Bathaie SZ, Miri H, Mohagheghi M-A, Mokhtari- Dizaji M, Shahbazfar A-A, Hasanzadeh H. Saffron aqueous extract inhibits the chemically-induced gastric cancer progression in the wistar albino rat. Iran J Basic Med Sci 2013; 16(1): 27-38.
28. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointol Oncol 2012; 3(3): 251-61.
29. Hudler P. Genetic aspects of gastric cancer instability. Sci World J 2012; 761909: 10.
30. Sousa MTDd, Savassi-Rocha PR, Cabral MMDÁ. Impact of using a lymph node revealing solution in surgical specimens for pathological staging of gastric cancer. J Brasil Patol Med Lab 2014; 50(6): 445-51.
31. Kaurah P, Huntsman DG. Hereditary Diffuse Gastric Cancer. In: Pagon RA, Adam MP, Ardinger HH, et al. Eds. GeneReviews(®). Seattle (WA): University of Washington, Seattle 1993.
32. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008; 266(2): 99-115.
33. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroentol Hepatol 2014; 11(11): 664-74.
34. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarker Prevent 2014; 23(5): 700-13.
35. Sallam RM. Proteomics in cancer biomarkers discovery: challenges and applications. Dis Markers 2015; 321370: 12.
36. Kobayashi E, Ueda Y, Matsuzaki S, et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarker Prevent 2012; 21(11): 1902-12.
37. Adam BL, Vlahou A, Semmes OJ, Wright GL. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics. 2001; 1(10): 1264-70.
38. Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E. Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Min Bone Met 2008; 5(2): 149-54.
39. Wang Y, Miller DJ, Clarke R. Approaches to working in high-dimensional data spaces: gene expression microarrays. Br J Cancer 2008; 98(6): 1023-8.
40. Phan JH, Quo C-F, Wang MD. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics. Prog Brain Res 2006; 158: 83-108.
41. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2010; 2(2): 125-48.
42. Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochem Biophys Acta 2009; 1796(2): 176-93.
43. Röcken C, Warneke V. Molecular pathology of gastric cancer. Der Pathol 2012; 33 (2): 235-40.
44. Berger F, Reiser MF. Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences? Theranostics 2013; 3(12): 943-52.
45. Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S, Jahn H. MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimers disease. PLoS One 2015; 10(5): 10(5): e0126423.
46. Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. BioMed Res Int 2015; e125094.
47. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2(5): 331-41.
48. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893-917.
49. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61(2): 69-90.
50. Cancer of the Stomach - SEER Stat Fact Sheets. http://seer.cancer.gov/statfacts/html/stomach.html.
51. Mirvish SS. Gastric cancer and salivary nitrate and nitrite. Nature 1985; 315(6019): 461-2.
52. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. New Eng J Med 1991; 325(16): 1127-31.
53. Lo SS, Wu CW, Hsieh MC, Kuo HS, Lui WY, P'Eng FK. Relationship between age and clinical characteristics of patients with gastric cancer. J Gastroentol Hepatol 1996; 11(6): 511-4.
54. Ding X, Yang S, Li W, et al. The potential biomarker panels for identification of major depressive disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis. PLoS One 2014; 9(5): e97479.
55. Leal MF, Assumpção PP, Smith MC, Burbano RR. Searching for gastric cancer biomarkers through proteomic approaches. J Gastroenterol Hepatol Res 2014; 3(3): 989-95.
56. Cortes DF, Kabulski JL, Lazar AC, Lazar IM. Recent advances in the mass spectrometric analysis of glycoproteins: capillary and microfluidic workflows. Electrophoresis 2011; 32(1): 14-29.
57. Tuli L, Ressom HW. LC-MS based detection of differential protein expression. J Prot Bioinf 2009; 2: 416-38.
58. Howat WJ, Lewis A, Jones P, et al. Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods 2014; 70(1): 34-8.
59. Ashraf GM, Banu N, Ahmad A, Singh LP, Kumar R. Purification, characterization, sequencing and biological chemistry of galectin-1 purified from Capra hircus (goat) heart. Prot J 2011; 30(1): 39-51.
60. Ashraf GM, Bilal N, Suhail N, Hasan S, Banu N. Glycosylation of purified buffalo heart galectin-1 plays crucial role in maintaining its structural and functional integrity. Biochemistry 2010; 75(12): 1450-7.
61. Ashraf GM, Greig NH, Khan TA, et al. Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13(7): 1280-93.
62. Ashraf GM, Perveen A, Tabrez S, et al. Altered galectin glycosylation: potential factor for the diagnostics and therapeutics of various cardiovascular and neurological disorders. Adv Exp Med Biol 2015; 822: 67-84.
63. Hasan SS, Ashraf GM, Banu N. Galectins - Potential targets for cancer therapy. Cancer Lett 2007; 253(1): 25-33.
64. Ashraf GM, Perveen A, Tabrez S, Zaidi SK, Kamal MA, Banu N. Studies on the role of goat heart galectin-1 as a tool for detecting post-malignant changes in glycosylation pattern. Saudi J Biol Sci 2015; 22(1): 85-9.
65. Ashraf GM, Perveen A, Zaidi SK, Tabrez S, Kamal MA, Banu N. Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent. Saudi J Biol Sci 2015; 22(1): 112-6.
66. Ashraf GM, Rizvi S, Naqvi S, et al. Purification, characterization, structural analysis and protein chemistry of a buffalo heart galectin-1. Amino Acids 2010; 39(5): 1321-32.
67. Lin L-L, Huang H-C, Juan H-F. Discovery of biomarkers for gastric cancer: a proteomics approach. J Prot 2012; 75(11): 3081-97.
68. Liu W, Liu B, Xin L, et al. Down-regulated expression of complement factor I: a potential suppressive protein for gastric cancer identified by serum proteome analysis. Clin Chim Acta 2007; 377(1-2): 119-26.
69. Chong PK, Lee H, Zhou J, et al. ITIH3 is a potential biomarker for early detection of gastric cancer. J Prot Res 2010; 9(7): 3671-9.
70. Hao Y, Yu Y, Wang L, et al. IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Prot Res 2008; 7(9): 3668-77.
71. Tsunemi S, Nakanishi T, Fujita Y, et al. Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Onc Rep 2010; 23(4): 949-56.
72. Juan H-F, Chen J-H, Hsu W-T, et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 2004; 4(9): 2766-75.
73. Ebert MPA, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling. J Prot Res 2004; 3(6): 1261-6.
74. Su Y, Shen J, Qian H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 2007; 98(1): 37-43.
75. Miyagi Y, Higashiyama M, Gochi A, et al. Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection. PLoS One 2011; 6(9): e24143.
76. Bones J, Byrne JC, O'Donoghue N, et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Prot Res 2011; 10(3): 1246-65.
77. Cohen M, Yossef R, Erez T, et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI- based peptidome and immuno-based clinical assays. PloS One 2011; 6(1): e14540.
78. Ko evar N, Odreman F, Vindigni A, Grazio SF, Komel R. Proteomic analysis of gastric cancer and immunoblot validation of poten- tial biomarkers. World J Gastroenterol 2012; 18(11): 1216-28.
79. Ebert MPA, Lamer S, Meuer J, et al. Identification of the thrombin light chain a as the single best mass for differentiation of gastric cancer patients from individuals with dyspepsia by proteome analysis. J Prot Res 2005; 4(2): 586-90.
80. Xia HH-X, Yang Y, Chu K-M, et al. Serum macrophage migrationinhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer 2009; 115(23): 5441-9.
81. Umemura H, Togawa A, Sogawa K, et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol 2011; 46(5): 577-85.
82. Cooke CL, Torres J, Solnick JV. Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes 2013; 4(6): 532-40.
83. Kon OL, Yip T-T, Ho MF, et al. The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics 2008; 1(54): 14.
84. Hsu P-I, Chen C-H, Hsieh C-S, et al. Alpha1-antitrypsin precursor in gastric juice is a novel biomarker for gastric cancer and ulcer. Clin Cancer Res 2007; 13(3): 876-83.
85. Kam SY, Hennessy T, Chua SC, et al. Characterization of the human gastric fluid proteome reveals distinct pH-dependent protein profiles: implications for biomarker studies. J Proteome Res 2011; 10(10): 4535-46
86. Balluff B, Rauser S, Meding S, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011; 179(6): 2720-9.
87. Melle C, Ernst G, Schimmel B, et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histoproteomic approach. J Proteome Res 2005; 4(5): 1799-804.
88. Kim HK, Reyzer ML, Choi IJ, et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010; 9(8): 4123-30.
89. Mohri Y, Mohri T, Wei W, et al. Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as [109] potential biomarkers for gastric cancer. Br J Cancer 2009; 101(2): 295-302.
90. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014; e852748.
91. Chen CD, Wang CS, Huang YH, et al. Overexpression of CLIC1 in human gastric carcinoma and its clinicopathological significance. Proteomics 2007; 7(1): 155-67.
92. Chen YR, Juan HF, Huang HC, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 2006; 5(10): 2727-42.
93. Fushida S, Yonemura Y, Urano T, et al. Expression of hepatocyte growth factor(hgf) and C-met gene in human gastric-cancer cell- lines. Int J Oncol 1993; 3(6): 1067-70.
94. Yonemura Y, Kaji M, Hirono Y, Fushida S, Tsugawa K, Fujimura T, et al. Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol 1996; 8(3): 555-60.
95. Yan GR, Xu SH, Tan ZL, Yin XF, He QY. Proteomics characterization of gastrokine 1-induced growth inhibition of gastric cancer cells. Proteomics 2011; 11(18): 3657-64.
96. Lin YF, Wu MS, Chang CC, et al. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol cell prot 2006; 5(8): 1484-96.
97. Liu J, Johnson TV, Lin J, et al. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 2007; 37(11): 3143-54.
98. Ebert MPA, Röcken C. Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol 2006; 18(8): 847-53.
99. Zhang J, Kang B, Tan X, et al. Comparative analysis of the protein profiles from primary gastric tumors and their adjacent regions: MAWBP could be a new protein candidate involved in gastric cancer. J Proteome Res 2007; 6(11): 4423-32.
100. Nishigaki R, Osaki M, Hiratsuka M, et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005; 5(12): 3205-13.
101. He Q-Y, Cheung YH, Leung SY, Yuen ST, Chu K-M, Chiu J-F. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004; 4(10): 3276-87.
102. Chen J, Kähne T, Röcken C, et al. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 2004; 3(5): 1009-16.
103. Kikuta K, Kubota D, Saito T, et al. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics 2012; 75(4): 1089-98.
104. Liu R, Li Z, Bai S, et al. Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics 2009; 8(1): 70-85.
105. Jia S-Q, Niu Z-J, Zhang L-H, et al. Identification of prognosis- related proteins in advanced gastric cancer by mass spectrometry- based comparative proteomics. J Can Res Clin Oncol 2009; 135(3): 403-11.
106. Koshikawa N, Moriyama K, Takamura H, et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Can Res 1999; 59(21): 5596-601.
107. Dohi T, Ohta S, Hanai N, Yamaguchi K, Oshima M. Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosa. J Biol Chem 1990; 265(14): 7880-5.
108. Jung J-H, Kim H-J, Yeom J, et al. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J Gastroenterol 2012; 47(1): 37-48.
109. Guo T, Zhu Y, Gan CS, et al. Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells. Mol Cell Proteomics 2010; 9(12): 2629-41.
110. Torti D, Sassi F, Galimi F, et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer 2012; 130(6): 1357-66.
111. Yang Y, Yixuan Y, Lim S-K, et al. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res 2010; 9(9): 4767-78.
112. Tseng C-W, Yang J-C, Chen C-N, et al. Identification of 14-3-3 in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics 2011; 11(12): 2423-39.
113. Kuramitsu Y, Baron B, Yoshino S, et al. Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res 2010; 30(11): 4459-65.
114. Kim HK, Park WS, Kang SH, et al. Mitochondrial alterations in human gastric carcinoma cell line. Am J Phys Cell Phys 2007; 293(2): C761-71.
115. Deng L, Su T, Leng A, et al. Upregulation of soluble resistance- related calcium-binding protein (sorcin) in gastric cancer. Med Onc 2010; 27(4): 1102-8.
116. Lahner E, Bernardini G, Possenti S, et al. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer. Int J Med Microbiol 301(2): 125-32.
117. Mini R, Bernardini G, Salzano AM, et al. Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 833(1): 63-79.
118. Das S, Sierra JC, Soman KV, et al. Differential Protein Expression Profiles of Gastric Epithelial Cells Following Helicobacter pylori Infection Using ProteinChips. J Proteome Res 2005; 4(3):920-30.
119. Holland C, Schmid M, Zimny-Arndt U, et al. Quantitative phosphoproteomics reveals link between Helicobacter pylori infection and RNA splicing modulation in host cells. Proteomics 2011; 11(14): 2798-811.
120. Backert S, Gressmann H, Kwok T, et al. Gene expression and protein profiling of AGS gastric epithelial cells upon infection with Helicobacter pylori. Proteomics 2005; 5(15): 3902-18.
121. Lin L-L, Chen C-N, Lin W-C, et al. Annexin A4: A novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl 2008; 2(4): 619-34.
122. Momynaliev KT, Kashin SV, Chelysheva VV, et al. Functional divergence of Helicobacter pylori related to early gastric cancer. J Proteome Res 2010; 9(1): 254-67.